Biobeat vs Cadence (2026)
Both watch patients who are not being watched, and they buy different things with the budget. Biobeat buys data, putting wearable monitors on patients who are otherwise checked every few hours, with FDA clearances for cuffless blood pressure, oxygen saturation and pulse rate measurement; its early warning score, marketed as AI, is described in the company's own paper as a set of expert defined rules, and no clearance covers it. Cadence buys labor, running chronic care management for older adults at home in partnership with health systems, and its home page says 99 percent of alerts are resolved without physician escalation. A program with no monitoring data needs the first; one with alerts nobody works needs the second. On Biobeat, ask about skin tone, because optical measurement varies with pigmentation.
- It changes what data exists, putting wearable monitors on patients otherwise checked intermittently, with a progression of clearances for cuffless measurement.
- One platform spans hospital wards, clinics, long term care and the home, the settings its clearance names, and excludes critical care.
- More frequent vitals can reach deterioration that happens between observations, and a peer reviewed study compared its score with NEWS on ward patients.
- It runs chronic care management for older adults at home in partnership with health systems, billed through an existing reimbursement pathway.
- It states how its supervised agents are used, with 99 percent of alerts resolved without physician escalation and care team calls answered within five minutes.
- Conditions and population are enumerated precisely, so a buyer can match the program against its own attributed panel.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Biobeat and Cadence are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Biobeat | Cadence |
|---|---|---|
| Primary category | Inpatient Deterioration & Risk Monitoring | Remote Monitoring & Chronic Care |
| Founded | 2016 | Not recorded |
| Headquarters | Petah Tikva, Israel | New York, New York |
| Website | bio-beat.com | cadence.care |
Side by Side
Select any grade to read the note behind it.
Product updates
The latest logged changes from each vendor, newest first, each linked to its source.
Cadence
-
Clinical evidence
Cadence reported an interim result from Hackensack Meridian Health, where more than 6,000 patients are managed at home with connected devices and a Cadence clinical team working under the health system's own protocols.
Source -
Regulatory / FDA
Cadence announced that its HypertensionOS software was selected by the FDA as the second participant in the TEMPO for Digital Health Devices Pilot.
Source
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Biobeat sells wearable vital sign monitors and a cloud platform for hospitals, long term care and home programs. The hardware is a single use chest patch and a wrist worn device built on a reflective photoplethysmography sensor, and from that optical signal the company derives blood pressure without a cuff (after calibration against a cleared cuff), oxygen saturation, pulse rate, respiratory rate, body temperature, stroke volume and cardiac output.
Source: AI Health Index, September 2026
AI enabled chronic care management for older adults, run in partnership with health systems: AI agents monitor daily vitals from connected devices in patients' homes and handle medication titration, lifestyle coaching, alert triage, care coordination and symptom assessment, working with an embedded clinical team for patients with hypertension, type 2 diabetes, heart failure and COPD. The company reports more than 20 partner health systems, 99 percent of alerts resolved without physician escalation and care team calls answered within five minutes.
Source: AI Health Index, September 2026
Questions buyers ask
How do Biobeat and Cadence handle patient data?
For Biobeat, the in hospital monitoring page describes a secure, HIPAA and GDPR compliant cloud based patient management system, and the clearance summaries describe the path: patch to a Bluetooth gateway to the cloud to a web application.
With Cadence, three data streams need answers: daily readings from connected devices in patients' homes, which accumulate over years in a chronic care program; text and phone conversations between patients and automated agents, including any call audio; and clinical staff access to partner health system records. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers.
The pigmentation problem sits on one side of this pair and it is consequential: optical vital sign measurement performs differently across skin tones, and Biobeat publishes no subgroup analysis for readings that feed its early warning score. Ask for it explicitly, and ask how the score's rules were set, since the clearances cover the measurements and not the score.
Cadence publishes no security attestation, retention position or training use statement, and its record system integration is claimed without naming the systems. Neither publishes pricing or a unit of pricing.